Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buckberg Cardi-Braun is a specialized cardioplegia solution manufactured by B. Braun, designed for use in the Buckberg protocol for myocardial protection during major cardiac surgery involving extracorporeal circulation. The solution is typically a blood-based cardioplegia, consisting of a mixture of the patient's own blood and a crystalloid concentrate. Its primary mechanism of action involves the induction of rapid, reversible diastolic cardiac arrest through a high concentration of potassium ions, which depolarizes the myocardial cell membrane and prevents electrical and mechanical activity. This state of arrest significantly reduces the heart's oxygen consumption and metabolic demand during the period of aortic cross-clamping. The formulation also includes buffers such as tromethamine (THAM) to counteract ischemia-induced acidosis, and other components like magnesium and dextrose to support metabolic requirements and reduce calcium-mediated injury during the ischemic period and subsequent reperfusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Buckberg Cardi-Braun.